BioVest offers cell culture products, instruments, and related contract services to research institutions, biotech firms, and pharmaceutical companies. The company is also developing a therapeutic cancer vaccine for follicular non-Hodgkin's lymphoma that is customized for individual patient use. The candidate, dubbed BiovaxID, is undergoing late-stage clinical trials. Its AutovaxID product is a cell culture instrument designed to ease use of BiovaxID. BioVest is 76% owned by Accentia Biopharmaceuticals. Both BioVest and Accentia filed for Chapter 11 bankruptcy in 2008 and are restructuring their operations.

Vernalis plc company was founded in 1986 and is based in Winnersh, the United Kingdom. Vernalis plc, a development stage pharmaceutical company, engages in de novo structure and fragment-based drug discovery, and pre-clinical and clinical development primarily in Europe and North America. It primarily involves in the research, development, and commercialization of pharmaceutical products for a range of medical disorders. The company’s products include Frovatriptan, a 5-HT1B/1D receptor agonist, which is approved as an acute oral treatment for migraine headache and its associated symptoms; and Apokyn, an acute intermittent therapy for the treatment of re-emergence of Parkinson’s disease symptoms associated with advanced Parkinson’s disease. Its product pipeline comprises V3381/Indantadol, a Phase IIb study novel small molecule with a dual mechanism for the treatment of neuropathic pain; V85546, a Phase I study selective MMP 12 inhibitor for inflammation; V1512/Levodopa methyl ester/carbidopa, a Phase II trial product for Parkinson’s disease treatment; V2006, an adenosine A2A receptor antagonist in Phase IIa study for the treatment of Parkinson’s disease; NVP-AUY922, a novel Hsp90 inhibitor, which is in Phase I program for the treatment of a range of cancers, including solid tumors and hematological cancers; V158866 Fatty Acid Amide Hydrolase, a pre-clinical stage product for pain management; V10153, a Phase IIa recombinant human thrombolytic protein for the treatment of acute ischemic stroke; and V24343, a Phase I study cannabinoid type 1 receptor antagonist for the treatment of obesity, diabetes, and related disorders.

Synteract, Inc. company has overseen hundreds of projects for clients that include biotechnology and pharmaceutical companies, as well as medical device makers. On top of research services, Synteract offers clients proprietary and customizable software solutions for managing research and trial data. The company's expertise covers a wide range of health issues, including oncology, HIV/AIDS, ophthalmology, and gastrointestinal disorders. Founded in 1995, Synteract maintains offices in San Diego, Philadelphia, and North Carolina.

ConjuChem Biotechnologies Inc. (ConjuChem) is a Canadian biotechnology company dedicated to the discovery of therapeutics with an initial focus on diabetes. The Company is focused on discovering and developing new drugs based on its technology platforms called Drug Affinity Complex (DAC) and Preformed Conjugate-Drug Affinity Complex (PC-DAC). The Company has developed the DAC Technology, a platform that enables the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. The Company also designs drugs to treat an array of pathologies, such as diabetes, cancer and human immunodeficiency virus (HIV). ConjuChem has multiple research programs in-house and has one product in clinical trials.

Pacific Biosciences, Inc. company was founded in 2004 and is based in Menlo Park, California. Pacific Biosciences, Inc. operates as a biotechnology company in North America. The company develops a transformative single-molecule (SMRT) DNA sequencing platform, which enables the observation of natural DNA synthesis by a DNA polymerase as it occurs; simplifies the resequencing of complex genomes; and the characterization of structural variation, including insertions, deletions, and rearrangements. Its products include SMRT chip, which enables the observation of individual fluorophores against a dense background of labeled nucleotides by maintaining a signal-to-noise ratio; and Phospholinked nucleotides that produce a natural DNA strand through DNA synthesis. Its product applications include de novo sequencing and resequencing. Pacific Biosciences, Inc. was formerly known as Nanofluidics, Inc.

Otsuka Pharmaceutical Europe was founded in 1998. Otsuka Pharmaceutical Europe markets drugs and health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. The company also conducts research and development of pharmaceuticals, focusing on the fields of gastroenterology, neurology, ophthalmology, and the cardiovascular system. Marketed drugs include schizophrenia treatment Abilify (through a partnership with Bristol-Myers Squibb), Adacolumn for inflammatory bowel disease, Mikelan for ocular glaucoma and hypertension, Pletal for peripheral vascular disease, and UBiT for gastrointestinal infection diagnosis.

Oncothyreon Inc. was founded in 1985 and is headquartered in Bellevue, Washington. Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon’s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Oncothyreon has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates is consisted of cancer vaccines and small molecule candidates. The Company’s wholly owned subsidiaries include Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.

Babraham Bioscience Technologies (BBT) is the operating company of the Babraham Institute, which works with companies around the world on pharmaceutical and biotechnology research projects. The company is committed to fostering innovation and bridging the gap from research to daily application. Through Babraham Technix, the company provides financial and administrative services to start-up biotech companies. It gives special emphasis to companies emerging from its Babraham Bioincubator division, which supports companies that research the role of genomics in healthcare. Commercial spin-offs from BBT include Discerna Ltd. and Orla Protein Technologies.

Hybrigenics wants to open a new pathway towards the fight against cancer. Established in 1997, the drug discovery company zeroes in on new drug targets and therapeutic biological components with the help of its computer programs involving protein sequencing and other high tech chemical screening techniques. What separates it from other drug researching companies is its Laboratory Information Management System (LIMS), a product that commercializes its library screening and navigating capabilities regarding DNA and other related biological sequencing. With its headquarters in Paris, Hybrigenics also owns Semaia BV, a subsidiary located in the Netherlands, and an additional office in the US.

ImClone Systems has one drug and it is making the most of it. The drug development company's only product on the market, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb in North America and with Merck KGaA elsewhere. ImClone is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. The company is also working on additional oncology-related antibody therapies. In 2008 ImClone was acquired by Eli Lilly for $6.5 billion, after rejecting bids from Bristol-Myers Squibb.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.